


**Supplemental Figure 1: CD80-Fc activates downstream signaling molecules EGR1-4 in Jurkat cells.** Jurkat cells were either untreated or incubated with agonist CD28 mAb, Troy-Fc, or CD80-Fc for two hours. RNA was then isolated, converted into cDNA, and the DNA analyzed by qRT-PCR for EGR1/2/3/4. Values were normalized to  $\beta$ -actin expression. Results are shown as fold change in expression level compared to untreated T cells. Statistical analysis was performed using Student's t test. \* =  $p < 0.05$ . Data are from one of three independent experiments.



**Supplemental Figure 2:** Human T cells remain activated in the presence of PDL1<sup>+</sup> tumor cells if  $\geq 1\mu\text{g/ml}$  of CD80-Fc is included in the cultures. PHA-activated human PBMC, PDL1<sup>+</sup> C8161 cells, and titered amounts of CD80-Fc were incubated as in figure 6 and T cell activation was assessed by measuring IFN $\gamma$  in the supernatants. Statistical analyses were performed using Student's t test. Points with \* are not statistically different from each other and are statistically different from all other values at  $p < 0.05$ .